Johnson & Johnson Statement on VENTURA Program

TITUSVILLE, N.J., March 6, 2025 – Johnson & Johnson has made the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder (aMDD) due to insufficient efficacy in the target patient population. The data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified. Based on the potential for this mechanism, the Company will explore future development opportunities for aticaprant in other areas of high unmet need. Full analyses from the VENTURA development program are underway and will be shared at a future medical meeting.

Johnson & Johnson continues to build on its leadership in Neuroscience, as demonstrated by the Company’s significant investments in its current pipeline and the planned acquisition of Intra-Cellular Therapies, Inc. The Company remains focused on driving innovation in neuropsychiatric and neurodegenerative disorders. Innovative Medicine still expects to deliver on its 5-7% CAGR¹ as presented in the 2023 Enterprise Business Review, including its ambition to become the #1 Neuroscience company worldwide.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research and Development, LLC and/or Johnson & Johnson.Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Janssen Research and Development, LLC nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Footnotes
¹ 2025-2030 CAGR based on risk-adjusted operational sales projections